Class / Patent application number | Description | Number of patent applications / Date published |
424229100 | Herpetoviridae (e.g., herpesvirus, Marek`s disease virus, laryngotracheitis virus, infectious bovine rhinotracheitis virus (IBR), infectious pustular vulvovaginitis virus, bovine herpes virus type 1, Aujeszky`s disease virus, feline rhinotracheitis virus, feline herpes virus, etc.) | 69 |
20080226677 | Recombinant virus vector for gene transfer into lymphoid cells - A recombinant herpesvirus, a method for producing the recombinant herpesvirus, and a pharmaceutical composition comprising the recombinant herpesvirus, are provided with a method for producing a recombinant herpesvirus using a BAC vector sequence. In addition, a vector comprising a herpesvirus genomic gene and a BAC vector sequence, a cell comprising the vector, and a nucleic acid cassette comprising a fragment, which is capable of homologous recombination with a herpesvirus genome, and a BAC vector sequence, are provided. | 09-18-2008 |
20080241187 | STABILIZATION OF VIRAL COMPOSITIONS - This invention concerns stabilized virus compositions, preferably a herpesvirus which may be an attenuated or genetically modified herpes simplex virus or varicella zoster virus, and a method of stabilizing viruses and immunizing preparations by the addition of sugars, preferably glucose and amino acids, preferably lysine. | 10-02-2008 |
20090060951 | DNA VACCINE FOR KOI HERPES VIRUS (KHV) DISEASE - The present invention provides a DNA vaccine for carps for inducing protective immunity against Koi herpesvirus (KHV). The DNA vaccine comprises a DNA comprising a nucleotide sequence encoding an immunogenic polypeptide against Koi herpesvirus (KHV) of carps, or an expression vector comprising the DNA as an active ingredient. | 03-05-2009 |
20090246226 | Avian vaccines possessing a positive marker gene - The present invention provides a poultry vaccine containing a positive marker gene. More specifically, recombinant turkey herpesvirus modified by the presence of an extraneous antigen gene that may be used as a positive marker to identify and track vaccinated animals is provided. When inoculated into host animals, a poultry vaccine comprising the recombinant turkey herpesvirus provided in the present invention can elicit serological immune responses to the marker gene product that may be detected by serological assays such as enzyme-linked immunosorbent assay and serum agglutination test, thus enabling easy identification and tracking of vaccinated animals. | 10-01-2009 |
20090252763 | BIOLOGICAL ADJUVANTS - A method of enhancing uptake of DNA by a host cell line comprises introducing the DNA into the host cell and contacting the host cell with non-infectious viral particles. The non-infectious particles may be L-particle or PREPS (pre-viral DNA replication envelope particles), for example, those derived from alpha herpesvirus. | 10-08-2009 |
20100119550 | RECOMBINANT MULTIVALENT VACCINE - The problems to be solved by the present invention are to provide: a recombinant varicella-zoster virus; a process for producing the same; a pharmacological composition containing a recombinant varicella-zoster virus; a vector containing a BAC vector sequence in the specific gene of a genomic gene of varicella-zoster virus; cells containing such a vector; a fragment capable of homologous recombination with a genome of varicella-zoster virus; a nucleic acid cassette containing the BAC vector sequence; and a multivalent vaccine. The above problems were solved by developing a process for producing a recombinant varicella-zoster virus, wherein the BAC vector sequence is inserted into a specific virus gene. | 05-13-2010 |
20100226940 | HERPES SIMPLEX VIRUS MUTANT ICP0 - A mutant herpesvirus that has a mutated gene that encodes a mutant infected cell protein 0 (ICP0) can be used in therapeutic methods as well as in diagnostics and research experiments. The encoded mutant ICP0 protein can be altered in one or more regions of ICP0 that are substantially conserved between two or more herpesviruses and/or within a phosphorylation region. The mutant herpesvirus can be substantially avirulent and immunogenic. | 09-09-2010 |
20100330122 | VARICELLA ZOSTER VIRUS VIRUS-LIKE PARTICLES (VLPs) AND ANTIGENS - The present invention discloses novel Varicella Zoster Virus (VZV) virus-like particles (VLPs) comprising glycoprotein E of VZV. The invention also discloses vaccine formulations of the VZV-VLPs and methods of inducing an immune response in subjects. | 12-30-2010 |
20120076823 | Vector - The present invention relates to a herpes virus vector which comprises a modified genomic sequence encoding a microRNA (miRNA) against a target sequence. The herpes virus vector may be used as or in a vaccine to prevent and/or treat a disease. | 03-29-2012 |
20120269854 | Method of Enhancing KSHV LANA1 Immunogenicity - An immunogenically-enhanced Kaposi sarcoma-associated herpesvirus latency-associated nuclear antigen 1 (“KSHV LANA1”) polypeptide and related methods of eliciting an immune response to KSHV LANA1 are provided. Also described herein is a novel polypeptide capable of inhibiting degradation of a protein or retarding synthesis of a protein when attached to or incorporated within that protein. | 10-25-2012 |
20130195918 | Equine Herpesvirus 1 Vaccine and Vector and Uses Thereof - We have constructed a mutant EHV-1 that is lacking the entire 12.7 kbp IR segment of the viral genome and found the mutant EHV-1 to be replication competent, to have the ability to replicate in mammalian cell types (including human cells), and to exhibit reduced virulence in the mouse model of EHV-1 virulence. | 08-01-2013 |
20130202638 | VACCINE AGAINST BETA-HERPESVIRUS INFECTION AND USE THEREOF - The present invention is related to a beta-herpesvirus, wherein the beta-herpesvirus is spread-deficient. | 08-08-2013 |
20140030292 | ANTIGEN DELIVERY PLATFORMS - This disclosure provides platforms for delivery of herpes virus proteins to cells, particularly proteins that form complexes in vivo. In some embodiments these proteins and the complexes they form elicit potent neutralizing antibodies. Thus, presentation of herpes virus proteins using the disclosed platforms permits the generation of broad and potent immune responses useful for vaccine development. | 01-30-2014 |
20140255447 | PRODUCTION OF AVIAN EMBRYO CELLS - The present invention relates to compositions and methods for preparing cells from avian embryos. The invention also relates to cultures of such cells and the uses thereof, particularly for producing viruses such as MDV. The invention also relates to methods for the preparation of vaccines using such cells or viruses. | 09-11-2014 |
20140348875 | KOI HERPESVIRUS VACCINE - The present invention relates to a recombinant Koi herpesvirus (KHV), methods for the production of such KHV, cells comprising such KHV and the use of such KHV as vector and in vaccines for the prevention and/or therapeutic treatment of a disease in fish caused by Koi herpesvirus in carp such as | 11-27-2014 |
20150376569 | PRODUCTION OF AVIAN EMBRYO CELLS - The present invention relates to compositions and methods for preparing cells from avian embryos. The invention also relates to cultures of such cells and the uses thereof, particularly for producing viruses such as MDV. The invention also relates to methods for the preparation of vaccines using such cells or viruses. | 12-31-2015 |
20160017284 | CYPRINID HERPESVIRUS II-SENSITIVE BRAIN TISSUE CELL LINE OF CARASSIUS AURATUS GIBELIO AND ESTABLISHING METHOD AND USE THEREOF - The present invention discloses a cyprinid herpesvirus II-sensitive brain tissue cell line of | 01-21-2016 |
20160051663 | METHODS AND DEVICES FOR CANINE HERPESVIRUS 1 (CHV-1) DETECTION AND PREVENTION - Methods for detection of canine herpes virus 1 (CHV-1) in archived paraffin-embedded tissue are provided. The methods use CHV-1 glycoprotein B (gB)-specific PCR to detect the CHV-1. A vaginal sleeve that protects puppies from contracting CHV-1 by contact with the mother's vaginal wall during birth is also provided. The sleeve is inserted into the vagina of a pregnant female dog prior to birth and puppies traverse the birth canal through the sleeve without coming into direct contact with vaginal tissue. Compositions and methods of immunizing against CHV-1 in dogs of all ages are also provided. | 02-25-2016 |
20160152956 | METHOD FOR SELECTING A PERMISSIVE CELL LINE FOR REPLICATING AVIAN VIRUSES | 06-02-2016 |
20190144507 | ANTIGEN DELIVERY PLATFORMS | 05-16-2019 |
20080226677 | Recombinant virus vector for gene transfer into lymphoid cells - A recombinant herpesvirus, a method for producing the recombinant herpesvirus, and a pharmaceutical composition comprising the recombinant herpesvirus, are provided with a method for producing a recombinant herpesvirus using a BAC vector sequence. In addition, a vector comprising a herpesvirus genomic gene and a BAC vector sequence, a cell comprising the vector, and a nucleic acid cassette comprising a fragment, which is capable of homologous recombination with a herpesvirus genome, and a BAC vector sequence, are provided. | 09-18-2008 |
20080241187 | STABILIZATION OF VIRAL COMPOSITIONS - This invention concerns stabilized virus compositions, preferably a herpesvirus which may be an attenuated or genetically modified herpes simplex virus or varicella zoster virus, and a method of stabilizing viruses and immunizing preparations by the addition of sugars, preferably glucose and amino acids, preferably lysine. | 10-02-2008 |
20090060951 | DNA VACCINE FOR KOI HERPES VIRUS (KHV) DISEASE - The present invention provides a DNA vaccine for carps for inducing protective immunity against Koi herpesvirus (KHV). The DNA vaccine comprises a DNA comprising a nucleotide sequence encoding an immunogenic polypeptide against Koi herpesvirus (KHV) of carps, or an expression vector comprising the DNA as an active ingredient. | 03-05-2009 |
20090246226 | Avian vaccines possessing a positive marker gene - The present invention provides a poultry vaccine containing a positive marker gene. More specifically, recombinant turkey herpesvirus modified by the presence of an extraneous antigen gene that may be used as a positive marker to identify and track vaccinated animals is provided. When inoculated into host animals, a poultry vaccine comprising the recombinant turkey herpesvirus provided in the present invention can elicit serological immune responses to the marker gene product that may be detected by serological assays such as enzyme-linked immunosorbent assay and serum agglutination test, thus enabling easy identification and tracking of vaccinated animals. | 10-01-2009 |
20090252763 | BIOLOGICAL ADJUVANTS - A method of enhancing uptake of DNA by a host cell line comprises introducing the DNA into the host cell and contacting the host cell with non-infectious viral particles. The non-infectious particles may be L-particle or PREPS (pre-viral DNA replication envelope particles), for example, those derived from alpha herpesvirus. | 10-08-2009 |
20100119550 | RECOMBINANT MULTIVALENT VACCINE - The problems to be solved by the present invention are to provide: a recombinant varicella-zoster virus; a process for producing the same; a pharmacological composition containing a recombinant varicella-zoster virus; a vector containing a BAC vector sequence in the specific gene of a genomic gene of varicella-zoster virus; cells containing such a vector; a fragment capable of homologous recombination with a genome of varicella-zoster virus; a nucleic acid cassette containing the BAC vector sequence; and a multivalent vaccine. The above problems were solved by developing a process for producing a recombinant varicella-zoster virus, wherein the BAC vector sequence is inserted into a specific virus gene. | 05-13-2010 |
20100226940 | HERPES SIMPLEX VIRUS MUTANT ICP0 - A mutant herpesvirus that has a mutated gene that encodes a mutant infected cell protein 0 (ICP0) can be used in therapeutic methods as well as in diagnostics and research experiments. The encoded mutant ICP0 protein can be altered in one or more regions of ICP0 that are substantially conserved between two or more herpesviruses and/or within a phosphorylation region. The mutant herpesvirus can be substantially avirulent and immunogenic. | 09-09-2010 |
20100330122 | VARICELLA ZOSTER VIRUS VIRUS-LIKE PARTICLES (VLPs) AND ANTIGENS - The present invention discloses novel Varicella Zoster Virus (VZV) virus-like particles (VLPs) comprising glycoprotein E of VZV. The invention also discloses vaccine formulations of the VZV-VLPs and methods of inducing an immune response in subjects. | 12-30-2010 |
20120076823 | Vector - The present invention relates to a herpes virus vector which comprises a modified genomic sequence encoding a microRNA (miRNA) against a target sequence. The herpes virus vector may be used as or in a vaccine to prevent and/or treat a disease. | 03-29-2012 |
20120269854 | Method of Enhancing KSHV LANA1 Immunogenicity - An immunogenically-enhanced Kaposi sarcoma-associated herpesvirus latency-associated nuclear antigen 1 (“KSHV LANA1”) polypeptide and related methods of eliciting an immune response to KSHV LANA1 are provided. Also described herein is a novel polypeptide capable of inhibiting degradation of a protein or retarding synthesis of a protein when attached to or incorporated within that protein. | 10-25-2012 |
20130195918 | Equine Herpesvirus 1 Vaccine and Vector and Uses Thereof - We have constructed a mutant EHV-1 that is lacking the entire 12.7 kbp IR segment of the viral genome and found the mutant EHV-1 to be replication competent, to have the ability to replicate in mammalian cell types (including human cells), and to exhibit reduced virulence in the mouse model of EHV-1 virulence. | 08-01-2013 |
20130202638 | VACCINE AGAINST BETA-HERPESVIRUS INFECTION AND USE THEREOF - The present invention is related to a beta-herpesvirus, wherein the beta-herpesvirus is spread-deficient. | 08-08-2013 |
20140030292 | ANTIGEN DELIVERY PLATFORMS - This disclosure provides platforms for delivery of herpes virus proteins to cells, particularly proteins that form complexes in vivo. In some embodiments these proteins and the complexes they form elicit potent neutralizing antibodies. Thus, presentation of herpes virus proteins using the disclosed platforms permits the generation of broad and potent immune responses useful for vaccine development. | 01-30-2014 |
20140255447 | PRODUCTION OF AVIAN EMBRYO CELLS - The present invention relates to compositions and methods for preparing cells from avian embryos. The invention also relates to cultures of such cells and the uses thereof, particularly for producing viruses such as MDV. The invention also relates to methods for the preparation of vaccines using such cells or viruses. | 09-11-2014 |
20140348875 | KOI HERPESVIRUS VACCINE - The present invention relates to a recombinant Koi herpesvirus (KHV), methods for the production of such KHV, cells comprising such KHV and the use of such KHV as vector and in vaccines for the prevention and/or therapeutic treatment of a disease in fish caused by Koi herpesvirus in carp such as | 11-27-2014 |
20150376569 | PRODUCTION OF AVIAN EMBRYO CELLS - The present invention relates to compositions and methods for preparing cells from avian embryos. The invention also relates to cultures of such cells and the uses thereof, particularly for producing viruses such as MDV. The invention also relates to methods for the preparation of vaccines using such cells or viruses. | 12-31-2015 |
20160017284 | CYPRINID HERPESVIRUS II-SENSITIVE BRAIN TISSUE CELL LINE OF CARASSIUS AURATUS GIBELIO AND ESTABLISHING METHOD AND USE THEREOF - The present invention discloses a cyprinid herpesvirus II-sensitive brain tissue cell line of | 01-21-2016 |
20160051663 | METHODS AND DEVICES FOR CANINE HERPESVIRUS 1 (CHV-1) DETECTION AND PREVENTION - Methods for detection of canine herpes virus 1 (CHV-1) in archived paraffin-embedded tissue are provided. The methods use CHV-1 glycoprotein B (gB)-specific PCR to detect the CHV-1. A vaginal sleeve that protects puppies from contracting CHV-1 by contact with the mother's vaginal wall during birth is also provided. The sleeve is inserted into the vagina of a pregnant female dog prior to birth and puppies traverse the birth canal through the sleeve without coming into direct contact with vaginal tissue. Compositions and methods of immunizing against CHV-1 in dogs of all ages are also provided. | 02-25-2016 |
20160152956 | METHOD FOR SELECTING A PERMISSIVE CELL LINE FOR REPLICATING AVIAN VIRUSES | 06-02-2016 |
20190144507 | ANTIGEN DELIVERY PLATFORMS | 05-16-2019 |
424230100 | Cytomegalovirus, varicella or herpes zoster virus, or Epstein-Barr virus | 14 |
20100068229 | RECOMBINANT ANTIGENS OF HUMAN CYTOMEGALOVIRUS (HCMV) - The invention described herein relates to a method for identifying the antigenic regions of HCMV proteins involved in the human B-cell response to HCMV infection, for combining such antigenic regions in the form of chimeric fusion products, and their use as diagnostic and immunogenic agents. | 03-18-2010 |
20110008387 | COMPOSITION CONTAINING HCMV PARTICLES - The present invention is related to a composition comprising an agent selected from the group comprising HCMV virions, HCMV dense bodies and HCMV NIEP, whereby the composition is capable of elucidating an immune response while the virions, the NIEP and/or the dense bodies being non-fusiogenic. | 01-13-2011 |
20110059133 | EX VIVO METHOD FOR PRODUCING A PREPARATION CONTAINING CD4+ T CELLS SPECIFIC FOR EBV STRUCTURAL ANTIGENS - The present invention discloses an ex vivo method for producing a preparation containing CD4+ T cells specific for EBV structural antigens for use in the prophylaxis and treatment of patients with a reduced T cell activity in order to prevent or treat growth of EBV infected B cells. | 03-10-2011 |
20110177124 | CODON-OPTIMIZED POLYNUCLEOTIDE-BASED VACCINES AGAINST HUMAN CYTOMEGALOVIRUS INFECTION - The invention is related to polynucleotide-based cytomegalovirus vaccines. In particular, the invention is plasmids operably encoding HCMV antigens, in which the naturally-occurring coding regions for the HCMV antigens have been modified for improved translation in human or other mammalian cells through codon optimization. HCMV antigens which are useful in the invention include, but are not limited to pp65, glycoprotein B (gB), IE1, and fragments, variants or derivatives of either of these antigens. In certain embodiments, sequences have been deleted, e.g., the Arg435-Lys438 putative kinase in pp65 and the membrane anchor and endocellular domains in gB. The invention is further directed to methods to induce an immune response to HCMV in a mammal, for example, a human, comprising delivering a plasmid encoding a codon-optimized HCMV antigen as described above. The invention is also directed to pharmaceutical compositions comprising plasmids encoding a codon-optimized HCMV antigen as described above, and further comprising adjuvants, excipients, or immune modulators. | 07-21-2011 |
20110189233 | Recombinant Varicella-Zoster Virus - A recombinant varicella-zoster virus; a process for producing the same; a pharmacological composition containing recombinant varicella-zoster virus; a vector containing a genomic gene of varicella-zoster virus and BAC vector sequence; cells containing the above vector; a fragment capable of homologous recombination with a genome of varicella-zoster virus; and a nucleic acid cassette containing the BAC vector sequence. For these, there is provided a process for producing recombinant varicella-zoster virus, comprising use of the BAC vector sequence. | 08-04-2011 |
20120034267 | INACTIVATED VARICELLA ZOSTER VIRUS VACCINES, METHODS OF PRODUCTION, AND USES THEREOF - The invention provides an inactivated varicella zoster virus (VZV), and compositions and vaccines comprising said inactivated VZV, wherein the infectivity of the VZV is undetectable and wherein the inactivated VZV induces an immune response against VZV when administered to a patient. In embodiments of the compositions described herein, the VZV is inactivated with gamma radiation. The invention also provides a method of preparing an inactivated VZV vaccine, the method comprising gamma irradiating a sample comprising a VZV using from about 5 kGy to about 50 kGy of gamma radiation. Also provided by the invention herein is a method of treatment of or immunization against HZ or other disease associated with the reactivation of VZV, the method comprising administering to a subject a vaccine or pharmaceutical composition comprising a therapeutically effective amount of an inactivated VZV and a pharmaceutically acceptable carrier, wherein the VZV is inactivated by gamma irradiation. | 02-09-2012 |
20130017217 | CODON-OPTIMIZED POLYNUCLEOTIDE-BASED VACCINES AGAINST HUMAN CYTOMEGALOVIRUS INFECTION - The invention relates to plasmids operably encoding HCMV antigens, in which the naturally-occurring coding regions for the HCMV antigens have been modified for improved translation in human or other mammalian cells through codon optimization. HCMV antigens, which are useful in the invention include, but are not limited to pp65, glycoprotein B (gB), IE1, and fragments, variants or derivatives of any of these antigens. In certain embodiments, sequences have been deleted, e.g., the Arg435-Lys438 putative kinase in pp65 and the membrane anchor and endocellular domains in gB. The invention is further directed to methods of inducing an immune response to HCMV in a mammal, for example, a human, comprising delivering a plasmid encoding a codon-optimized HCMV antigen as described above. The invention is also directed to pharmaceutical compositions comprising plasmids encoding a codon-optimized HCMV antigen as described above, and further comprising adjuvants, excipients, or immune modulators. | 01-17-2013 |
20130028935 | COMPOSITION CONTAINING HCMV PARTICLES - The present invention is related to a composition comprising an agent selected from the group comprising HCMV virions, HCMV dense bodies and HCMV NIEP, whereby the composition is capable of elucidating an immune response while the virions, the NIEP and/or the dense bodies being non-fusiogenic. | 01-31-2013 |
20130045230 | COMPOSITION CONTAINING HCMV PARTICLES - The present invention is related to a composition comprising an agent selected from the group comprising HCMV virions, HCMV dense bodies and HCMV NIEP, whereby the composition is capable of elucidating an immune response while the virions, the NIEP and/or the dense bodies being non-fusiogenic. | 02-21-2013 |
20140127265 | GUINEA PIG CYTOMEGALOVIRUS (CIDMTR Strain) - The present disclosure provides an isolated or purified guinea pig cytomegalovirus (GPCMV) Strain CIDMTR, glycoproteins from GPCMV Strain CIDMTR, and methods of use thereof. | 05-08-2014 |
20140178432 | PRODUCTION OF DENSE BODIES (DB) FROM HCMV-INFECTED CELLS - The invention relates to the production of dense bodies (DB) and to a pharmaceutical composition containing DB. | 06-26-2014 |
20150044258 | PROCESS FOR T CELL EXPANSION - An in vitro expansion process for rapid expansion of antigen specific T cells, such as allogeneic antigen specific T cells comprising the steps culturing in a gas permeable vessel a population of PBMCs (such as allogeneic PBMCs) in the presence of antigen, for example a peptide or peptide mix relevant to a target antigen(s), in the presence of an exogenous cytokine characterized in that the expansion to provide the desired population of T cells is 14 days or less, for example 9, 10, 11 or 12 days, such as 10 days. The disclosure also extends to T cell populations generated by and obtained from the method and the use of same in therapy. | 02-12-2015 |
20150307850 | CONDITIONAL REPLICATING VIRAL VECTORS - The present invention relates to a cytomegalovirus (CMV) which has been recombinantly altered to express a heterologous polypeptide and to allow for external control of viral replication. The heterologous polypeptide may be a polypeptide of interest such as an antigen, antibody or immune modulator. The CMV vectors of the invention are replication defective, or chemically controllable replication capable, or replication competent. The present invention also relates to uses of the CMV vectors such as inducing an immune response to an antigen or expressing an antibody or immune modulator in vivo. Compositions comprising the CMV expressing the heterologous polypeptide are also encompassed by the present invention. | 10-29-2015 |
20150359879 | RECOMBINANT PARTICLE BASED VACCINES AGAINST HUMAN CYTOMEGALOVIRUS INFECTION - The invention relates to gene and protein assemblies in the form of virus-like particles and protein complexes for use as prophylactic or therapeutic vaccines, and diagnostic and R&D tools for human cytomegalovirus (HCMV) and other herpes viruses. The virus-like particles comprise one or more capsid proteins from a herpes virus or a retrovirus, three or more CMV surface proteins and optionally tegument proteins. The assemblies are prepared using a technology combining recombinant DNA with disposable cell culture and purification techniques. | 12-17-2015 |
424231100 | Herpes simplex virus (e.g., HSV-1, HSV-2, etc.) | 35 |
20080241188 | Turkey herpesvirus vectored recombinant containing avian influenza genes - The present invention provides a recombinant turkey herpesvirus modified by the presence of the cDNA encoding the hemagglutinin protein of avian influenza virus under a promoter. A poultry vaccine comprising the recombinant turkey herpesvirus described in the present invention can induce serological responses that may be easily detected by the hemagglutination inhibition assay but not by commercially available diagnostic ELISA kits; thus enabling easy differentiation between vaccination and field infection. | 10-02-2008 |
20090098162 | Herpes simplex virus combined subunit vaccines and methods of use thereof - This invention provides vaccines comprising two or more recombinant Herpes Simplex Virus (HSV) proteins selected from a gD protein, a gC protein and a gE protein; and methods of vaccinating a subject against HSV and treating, impeding, inhibiting, reducing the incidence of, or suppressing an HSV infection or a symptom or manifestation thereof, comprising administration of a vaccine of the present invention. | 04-16-2009 |
20090246227 | METHODS OF USE FOR HSV-1 AND HSV-2 VACCINES - This invention provides methods of treating, suppressing, inhibiting, reducing an incidence, reducing the pathogenesis of, ameliorating the symptoms of, or ameliorating the secondary symptoms of a primary or recurring Herpes Simplex Virus (HSV) infection, or prolonging the latency to a relapse of an HSV infection, and disorders and symptoms associated with same and inducing an anti-HSV immune response in a subject comprising the step of contacting the subject with a composition comprising a mutant HSV strain comprising an inactivating mutation in a Us8 gene, followed by a second contacting with the composition. | 10-01-2009 |
20090274728 | Mutant Viruses - An herpes simplex virus wherein the herpes simplex virus genome comprises nucleic acid encoding an antisense to the squamous cell carcinoma related oncogene (asSCCRO); and an herpes simplex virus wherein the herpes simplex virus genome comprises nucleic acid encoding a short interfering ribonucleic acid (siRNA) molecule that is capable of repressing or silencing expression of squamous cell carcinoma related oncogene (SCCRO) nucleic acid or polypeptide are disclosed together with methods for generation and applications of such viruses. | 11-05-2009 |
20090311290 | Urogenital or anorectal transmucosal vaccine delivery system - The invention is directed to a suppository based vaccine delivery system for immunizing against urogenital and anorectally transmitted infectious disease in humans and animals and a method for treating the same. More particularly, this invention is directed to a suppository based vaccine delivery system for the prophylaxis against or treatment of urogenital or anorectal transmitted infectious diseases, such as from viral or microbial pathogens. The suppository based delivery system comprises vaccine and/or vaccine adjuvant(s) comprised of whole or fractionated viral or other microbial pathogens, or their purified cellular constituents, whether native, mutated, synthetic, cloned or recombinantly expressed, that consists of nucleic acids, proteins, lipids or other antigenic determinants capable of producing humoral or cellular-mediated immunity in humans or animals; and a polyethylene glycol base; wherein the suppository is adapted to be inserted into a bodily orifice of a human or animal so as to allow the suppository to be in contact with tissue of the bodily orifice to facilitate transfer of vaccine or vaccine adjuvant(s) material therethrough. | 12-17-2009 |
20100040651 | Compositions and Methods for Vaccinating Against HSV-2 - This invention relates to a method for systemic immune activation which is effective for eliciting both a systemic, non-antigen specific immune response and a strong antigen-specific immune response in a mammal. The method is particularly effective for protecting a mammal from herpes simplex virus. Also disclosed are therapeutic compositions useful in such a method. | 02-18-2010 |
20100055132 | NON-SPECIFIC DELAYED-TYPE HYPERSENSITIVITY RESPONSE TO TREAT HERPES SIMPLEX VIRUS INFECTION - A method is presented for treating herpes simplex virus (HSV) infection comprising: (a) locally administering a substance that induces a delayed type hypersensitivity (DTH) response to a patient at a site of an HSV lesion to induce a DTH response at the site of the lesion during one or more outbreaks of the HSV infection. | 03-04-2010 |
20100092515 | HERPES SIMPLEX VIRUSES AND METHODS OF VIRAL REPLICATION - A herpes simplex virus is disclosed in which the herpes simplex virus genome comprises a nucleic acid sequence encoding an ING4 polypeptide. | 04-15-2010 |
20100098726 | VIRUS-EXPRESSING HOST COSTIMULATION MOLECULES - An antiviral vaccine that encodes costimulation molecules for increasing immune response to the particular virus at issue is provided herein. In an illustrative embodiment, in mice lacking both B7-1 and B7-2 (B7KO), the increased severity of HSV infection has confirmed the importance of these molecules in generation of HSV-specific immunity. To test the concept that B7-1 or B7-2 expression by replication-defective HSV could augment its immunogenicity and protective capacity, the present inventors constructed replication-defective HSV-2 encoding B7-1 or B7-2. Both viruses partially reconstituted immune responses to HSV compared with replication-defective virus alone when used to immunize B7KO mice, indicating that the increased responsiveness to virus could be attributed to virus-encoded B7 molecules. | 04-22-2010 |
20100158949 | Compositions and Methods for Vaccinating Against HSV-2 - This invention relates to a method for systemic immune activation which is effective for eliciting both a systemic, non-antigen specific immune response and a strong antigen-specific immune response in a mammal. The method is particularly effective for protecting a mammal from herpes simplex virus. Also disclosed are therapeutic compositions useful in such a method. | 06-24-2010 |
20100166798 | METHOD AND KIT FOR TREATMENT/PREVENTION OF HAIR LOSS - The method includes the steps of cleansing of the scalp sufficiently to remove material which would otherwise block antiviral medication from reaching hair follicles, heating the scalp to increase the absorption of the antiviral medication and applying the antiviral medication to the scalp in effective amount to suppress viral replication or viral activation present in the nerves leading to the scalp. | 07-01-2010 |
20110059134 | PREVENTION OF RECURRENT VIRAL DISEASE - The present invention discloses compositions and methods for ameliorating or reducing recurrent viral disease, which compositions and methods result in an increase in virus specific immunoglobulin subclasses reflective of a preferential Th1 response. | 03-10-2011 |
20110135687 | RAPID, EFFICIENT PURIFICATION OF HSV-SPECIFIC T-LYMPHOCYTES AND HSV ANTIGENS IDENTIFIED VIA SAME - Described is a method of identifying an immunologically active antigen of a virus that attacks skin, as well as a method of enriching a population of lymphocytes for T lymphocytes that are specific to a virus that attacks skin. Also provided are HSV antigens and epitopes that are useful for the prevention and treatment of HSV infection that have been identified via the methods of the invention. T-cells having specificity for antigens of the invention have demonstrated cytotoxic activity against cells loaded with virally-encoded peptide epitopes, and in many cases, against cells infected with HSV. The identification of immunogenic antigens responsible for T-cell specificity provides improved anti-viral therapeutic and prophylactic strategies. Compositions containing antigen or polynucleotides encoding antigens of the invention provide effectively targeted vaccines for prevention and treatment of HSV infection. | 06-09-2011 |
20110177125 | HSV-1 AND HSV-2 VACCINES AND METHODS OF USE THEREOF - This invention provides methods of vaccinating a subject against a Herpes Simplex Virus (HSV) infection and disorders and symptoms associated with same, and impeding, inhibiting, reducing the incidence of, and suppressing HSV infection, neuronal viral spread, formation of zosteriform lesions, herpetic ocular disease, herpes-mediated encephalitis, and genital ulcer disease in a subject, comprising the step of contacting the subject with a mutant strain of the HSV, containing an inactivating mutation in a gene encoding a gE, gl, Us9, or other proteins. | 07-21-2011 |
20110256176 | HERPES SIMPLEX VIRUS COMBINED SUBUNIT VACCINES AND METHODS OF USE THEREOF - This invention provides vaccines comprising two or more recombinant Herpes Simplex Virus (HSV) proteins selected from a gD protein, a gC protein and a gE protein; and methods of impeding immune evasion by HSV thereby vaccinating a subject against HSV and treating, suppressing, inhibiting, and/or reducing an incidence of an an HSV infection or a symptom or manifestation thereof, comprising administration of a vaccine of the present invention. | 10-20-2011 |
20120114695 | HSV-1 AND HSV-2 VACCINES AND METHODS OF USE THEREOF - This invention provides methods of treating, suppressing, inhibiting, reducing an incidence, reducing the pathogenesis of, ameliorating the symptoms of, or ameliorating the secondary symptoms of a primary or recurring Herpes Simplex Virus (HSV) infection, or prolonging the latency to a relapse of an HSV infection, and disorders and symptoms associated with same and inducing an anti-HSV immune response in a subject comprising the step of contacting the subject with a composition comprising a mutant HSV strain comprising an inactivating mutation in a Us8 gene, followed by a second contacting with the composition. | 05-10-2012 |
20120328655 | IMMUNOGENIC COMPOSITIONS AND METHODS OF USING THE COMPOSITIONS FOR INDUCING HUMORAL AND CELLULAR IMMUNE RESPONSES - Compositions and methods are provided herein for improved dual immunization strategies that induce in a subject an immune response that includes a humoral immune response and cellular immune response, both CD4 and CD8 T lymphocyte immune responses, thereby providing a complete adaptive immune response to one or more antigens. The methods described are therefore useful for treating and/or preventing (i.e., reducing the likelihood or risk of occurrence) different diseases, disorders, and conditions such as cancers and infectious diseases for which induction of both a humoral immune response and cellular immune response is desired and beneficial. | 12-27-2012 |
20120328656 | COMPOSITIONS AND METHODS FOR VACCINATING AGAINST HSV-2 - This invention relates to a method for systemic immune activation which is effective for eliciting both a systemic, non-antigen specific immune response and a strong antigen-specific immune response in a mammal. The method is particularly effective for protecting a mammal from herpes simplex virus. Also disclosed are therapeutic compositions useful in such a method. | 12-27-2012 |
20120328657 | COMPOSITIONS AND METHODS FOR VACCINATING AGAINST HSV-2 - This invention relates to a method for systemic immune activation which is effective for eliciting both a systemic, non-antigen specific immune response and a strong antigen-specific immune response in a mammal. The method is particularly effective for protecting a mammal from herpes simplex virus. Also disclosed are therapeutic compositions useful in such a method. | 12-27-2012 |
20120328658 | COMPOSITIONS AND METHODS FOR VACCINATING AGAINST HSV-2 - This invention relates to a method for systemic immune activation which is effective for eliciting both a systemic, non-antigen specific immune response and a strong antigen-specific immune response in a mammal. The method is particularly effective for protecting a mammal from herpes simplex virus. Also disclosed are therapeutic compositions useful in such a method. | 12-27-2012 |
20130034586 | AVIRULENT ONCOLYTIC HERPES SIMPLEX VIRUS STRAINS ENGINEERED TO COUNTER THE INNATE HOST RESPONSE - The present invention relates to an avirulent, oncolytic herpes simplex virus modified from a wild-type herpes simplex virus so that both γ | 02-07-2013 |
20130202639 | Synthetic Herpes Simplex Viruses for Treatment of Cancers - New recombinant oncolytic viral vectors have been constructed based on a known herpes simplex virus-1 with a single 34.5 gene and a synctial mutation (called OncSyn (OS) virus), which was designed to be more immunogenic than the parental OS virus largely due to deletion of the viral gene viral host shutoff (vhs) gene (the “OSV” virus). In another embodiment, the OSV virus was constructed to constitutively express 15-PGDH (the “OSVP” virus), the principal enzyme responsible for degradation of PGE2. OSVP was shown to decrease both breast tumors and prostate cancer tumors in mice models. In addition, OSVP was shown to trigger substantial inflammatory cytokine production and pro mote anti-tumor immune responsiveness. These altered viruses, OSV and OSVP, can be used to treat various cancers including breast, prostate, liver, colon, and other tissues. Other exogenous genes can be added to either OSV or OSVP to improve the therapeutic response. | 08-08-2013 |
20130202640 | COMPOSITIONS AND METHODS FOR VACCINATING AGAINST HSV-2 - This invention relates to a method for systemic immune activation which is effective for eliciting both a systemic, non-antigen specific immune response and a strong antigen-specific immune response in a mammal. The method is particularly effective for protecting a mammal from herpes simplex virus. Also disclosed are therapeutic compositions useful in such a method. | 08-08-2013 |
20130273107 | COMPOSITIONS AND METHODS FOR VACCINATING AGAINST HSV-2 - This invention relates to a method for systemic immune activation which is effective for eliciting both a systemic, non-antigen specific immune response and a strong antigen-specific immune response in a mammal. The method is particularly effective for protecting a mammal from herpes simplex virus. Also disclosed are therapeutic compositions useful in such a method. | 10-17-2013 |
20130273108 | COMPOSITIONS AND METHODS FOR VACCINATING AGAINST HSV-2 - This invention relates to a method for systemic immune activation which is effective for eliciting both a systemic, non-antigen specific immune response and a strong antigen-specific immune response in a mammal. The method is particularly effective for protecting a mammal from herpes simplex virus. Also disclosed are therapeutic compositions useful in such a method. | 10-17-2013 |
20130280299 | VIRAL VECTORS AND THEIR USE IN THERAPEUTIC METHODS - The invention provides viral vectors (e.g., herpes viral vectors) and methods of using these vectors to treat disease. | 10-24-2013 |
20140193460 | HERPES VIRUS VACCINE AND METHODS OF USE - Provided herein are, inter alia, vaccines and methods of using the same for the treatment or prevention of Herpesvirus infections. | 07-10-2014 |
20140314811 | HERPES SIMPLEX VIRUS VACCINES - The present invention is directed to Herpes simplex-2 viruses that may be used in vaccines to immunize patients against genital herpes. | 10-23-2014 |
20140363469 | VIRAL ATTENUATION AND VACCINE PRODUCTION - The present invention is directed to the generation of attenuated viruses or viral transcripts for the production of vaccines by incorporating microRNA binding sites within the viral target sequence of the pathogen. | 12-11-2014 |
20140370055 | COMPOSITIONS AND METHODS FOR VACCINATING AGAINST HSV-2 - This invention relates to therapeutic polynucleotide compositions and methods for systemic immune activation which are effective for eliciting both a systemic, non-antigen specific immune response and a strong antigen-specific immune response in mammals. The polynucleotide compositions are particularly effective for protecting mammals from herpes simplex virus (HSV), such as HSV gD2 polypeptides. | 12-18-2014 |
20150010596 | COMPOSITIONS AND METHODS FOR VACCINATING AGAINST HSV-2 - This invention relates to therapeutic compositions and methods for systemic immune activation which are effective for eliciting both a systemic, non-antigen specific immune response and a strong antigen-specific immune response in mammals. The methods are particularly effective for protecting mammals from herpes simplex virus. | 01-08-2015 |
20150010597 | COMPOSITIONS AND METHODS FOR VACCINATING AGAINST HSV-2 - This invention relates to therapeutic polynucleotide compositions and methods for systemic immune activation which are effective for eliciting both a systemic, non-antigen specific immune response and a strong antigen-specific immune response in mammals. The polynucleotide compositions are particularly effective for protecting mammals from herpes simplex virus (HSV), such as HSV gD2, VP11/12, and VP13/14 polypeptides. | 01-08-2015 |
20150030631 | COMPOSITIONS AND METHODS FOR VACCINATING AGAINST HSV-2 - This invention relates to therapeutic compositions and methods for systemic immune activation which are effective for eliciting both a systemic, non-antigen specific immune response and a strong antigen-specific immune response in mammals. The methods are particularly effective for protecting mammals from herpes simplex virus. | 01-29-2015 |
20150290315 | HSV-1 AND HSV-2 VACCINES AND METHODS OF USE THEREOF - This invention provides methods of treating, suppressing, inhibiting, reducing an incidence, reducing the pathogenesis of, ameliorating the symptoms of, or ameliorating the secondary symptoms of a primary or recurring Herpes Simplex Virus (HSV) infection, or prolonging the latency to a relapse of an HSV infection, and disorders and symptoms associated with same and inducing an anti-HSV immune response in a subject comprising the step of contacting the subject with a composition comprising a mutant HSV strain comprising an inactivating mutation in a Us8 gene, followed by a second contacting with the composition. | 10-15-2015 |
20220133881 | HERPESVIRUS COMPOSITIONS AND RELATED METHODS - The present disclosure relates to liquid and dried compositions comprising a live, attenuated or genetically modified herpesvirus and methods of preparing such compositions, in one aspect, the composition comprises at least two or more pharmaceutically acceptable excepients, at least one of which is histidine and at least one of which is a sugar or sugar alcohol. The compostions retain a sufficiently high infectious titre following storage or large-scale manufacturing steps, such as lyophilization. | 05-05-2022 |